Detalhe da pesquisa
1.
Characterization of Pharmacokinetics, Biotransformation and Elimination of Pomotrelvir Orally Administered in Healthy Male Adults Using Two [14C]-Labeled Microtracers with Separate Labeling Positions.
Drug Metab Dispos
; 51(12): 1607-1614, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37684056
2.
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Xenobiotica
; 52(6): 555-566, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052821
3.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 311-22, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639348
4.
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Br J Cancer
; 118(8): 1042-1050, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29551775
5.
Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
Drug Metab Dispos
; 45(3): 294-305, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993930
6.
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Br J Clin Pharmacol
; 83(4): 846-854, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27859472
7.
Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.
Eur J Clin Pharmacol
; 71(6): 707-714, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25939708
8.
Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
Antimicrob Agents Chemother
; 56(4): 2067-73, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22252798
9.
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(5): 640-653, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172043
10.
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
Mol Cancer Ther
; 19(5): 1210-1217, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32127466
11.
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Clin Cancer Res
; 26(10): 2308-2317, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969330
12.
Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.
J Clin Pharmacol
; 49(7): 816-23, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19443680
13.
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
J Antimicrob Chemother
; 62(4): 780-3, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18586659
14.
Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity.
Clin Pharmacokinet
; 47(11): 753-64, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18840030
15.
Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay.
J Clin Endocrinol Metab
; 92(6): 2307-11, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17405837
16.
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
Clin Drug Investig
; 37(3): 303-309, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27910036
17.
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
J Clin Pharmacol
; 57(4): 484-492, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27558232
18.
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Clin Pharmacokinet
; 56(5): 515-523, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27638334
19.
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Clin Ther
; 39(2): 359-367, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28161120
20.
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
J Med Chem
; 60(20): 8369-8384, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949521